SCHEMBL15917441

SCHEMBL15917441

COc1cc2c(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3)ccnc2cc1OCC(=O)NO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 11/20 0.58
AXL P30530 11/20 0.58
KDR P35968 5/20 0.58
MERTK Q12866 3/20 0.58
RET P07949 2/20 0.58
KIT P10721 2/20 0.58
FLT3 P36888 2/20 0.58
FLT1 P17948 2/20 0.58
AURKB Q96GD4 2/20 0.58
AURKA O14965 1/20 0.58
RIPK2 O43353 1/20 0.58
ABCB11 O95342 1/20 0.58
ABL1 P00519 1/20 0.58
EGFR P00533 1/20 0.58
ERBB2 P04626 1/20 0.58
NTRK1 P04629 1/20 0.58
LCK P06239 1/20 0.58
PGR P06401 1/20 0.58
LYN P07948 1/20 0.58
CHRM2 P08172 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15917725 1.00 MET (0.58) METAXLKDRMERTKRET
SCHEMBL15917971 0.93 MET (0.57) METAXLKDRMERTKRET
SCHEMBL15918227 0.93 MET (0.57) METAXLKDRMERTKRET
SCHEMBL15918046 0.92 MET (0.58) METAXLKDRMERTKRET
SCHEMBL15917296 0.92 MET (0.58) METAXLKDRMERTKRET
SCHEMBL15918320 0.92 MET (0.62) METAXLKDRMERTKRET
SCHEMBL15918222 0.92 MET (0.62) METAXLKDRMERTKRET
SCHEMBL372017 0.91 MET (0.66) METAXLKDRMERTKRET
SCHEMBL29883010 0.91 MET (0.66) METAXLKDRMERTKRET
SCHEMBL15918345 0.91 HDAC2 (0.62) METAXLKDRMERTKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2769976-B1 HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF BEIJING KONRUNS PHARMACEUTICAL CO LTD (CN) 2017-08-02 EP claimed
US-9186318-B2 Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) 2015-11-17 US claimed
EP-2769976-A1 HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF Beijing Konruns Pharmaceutical Co., Ltd. (CN) 2014-08-27 EP claimed
US-20140221425-A1 Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) 2014-08-07 US claimed
EP-2769976-B1 HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF BEIJING KONRUNS PHARMACEUTICAL CO LTD (CN) 2017-08-02 EP disclosed
US-9186318-B2 Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) 2015-11-17 US disclosed
EP-2769976-A1 HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF Beijing Konruns Pharmaceutical Co., Ltd. (CN) 2014-08-27 EP disclosed
US-20140221425-A1 Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221425-A1 Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof HDAC5, HDAC1, HDAC7 MET 1782/4885AXL 2018/4885KDR 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.